Bortezomib in Treating Patients With Advanced or Metastatic Transitional Cell Cancer of the Bladder, Renal Pelvis, or Ureter



Status:Completed
Conditions:Cancer, Cancer, Cancer, Cancer, Bladder Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:4/21/2016
Start Date:September 2003

Use our guide to learn which trials are right for you!

A Phase II Study of PS-341 in Advanced or Metastatic Urothelial Cancer (Transitional Cell Cancer of the Bladder, Ureter, and Renal Pelvis)

RATIONALE: Bortezomib may stop the growth of tumor cells by blocking the enzymes necessary
for their growth.

PURPOSE: This phase II trial is studying how well bortezomib works in treating patients with
advanced or metastatic transitional cell cancer of the bladder, renal pelvis, or ureter.

OBJECTIVES:

- Determine the response rate and duration of response in patients with advanced or
metastatic transitional cell cancer of the bladder, renal pelvis, or ureter when
treated with bortezomib.

- Determine the 1-year, median, and overall survival rate of patients treated with this
drug.

- Determine the stable disease rate and duration and time to progression in patients
treated with this drug.

- Determine the toxicity of this drug in these patients.

- Correlate baseline and post-treatment levels of NF-kappaB and HIF-1 alpha in tumor
biopsies with clinical outcome in patients treated with this drug.

OUTLINE: This is a nonrandomized, open-label, multicenter study.

Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Courses repeat
every 21 days in the absence of disease progression or unacceptable toxicity. Patients in
complete remission (CR) may receive up to 2 courses after confirmation of CR.

Patients are followed within 3 weeks and then every 3 months thereafter.

PROJECTED ACCRUAL: A total of 20-35 patients will be accrued for this study within
approximately 6.6-17.5 months.

DISEASE CHARACTERISTICS:

- Histologically or cytologically confirmed transitional cell cancer of the urothelium,
including the bladder, renal pelvis, or ureter

- Advanced or metastatic disease

- At least 1 unidimensionally measurable lesion

- At least 20 mm by conventional techniques OR at least 10 mm by spiral CT scan

- The following are not considered measurable disease:

- Bone lesions

- Leptomeningeal disease

- Ascites

- Pleural/pericardial effusion

- Inflammatory breast disease

- Lymphangitis cutis/pulmonis

- Abdominal masses that are not confirmed and followed by imaging techniques

- Cystic lesions

- No known brain metastases

PATIENT CHARACTERISTICS:

Age

- 18 and over

Performance status

- ECOG 0-1 OR

- Karnofsky 80-100%

Life expectancy

- More than 3 months

Hematopoietic

- WBC at least 3,000/mm^3

- Absolute neutrophil count at least 1,500/mm^3

- Platelet count at least 100,000/mm^3

Hepatic

- Bilirubin no greater than 1.25 times upper limit of normal (ULN)

- AST/ALT no greater than 3 times ULN (less than 5 times ULN if liver metastases are
present)

Renal

- Creatinine no greater than 1.5 times ULN OR

- Creatinine clearance at least 45 mL/min

Cardiovascular

- No symptomatic congestive heart failure

- No unstable angina pectoris

- No cardiac arrhythmia

Other

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception

- Able and willing to undergo biopsy of tumor lesions

- No other primary cancer requiring treatment within the past 3 years except curatively
treated nonmelanoma skin cancer or carcinoma in situ of the cervix

- No grade 1 or greater peripheral neuropathy

- No ongoing or active infection

- No other concurrent uncontrolled illness

- No psychiatric illness or social situation that would preclude study compliance

PRIOR CONCURRENT THERAPY:

Biologic therapy

- Not specified

Chemotherapy

- No more than 2 prior chemotherapy regimen for metastatic disease

- Prior neoadjuvant or adjuvant therapy allowed provided it was completed more
than 12 months prior to study entry

- Patients who relapse within 12 months after completion of neoadjuvant or
adjuvant therapy are allowed provided they did not receive chemotherapy for
recurrent disease

- More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin)
and recovered

- Prior chemotherapy as a radiosensitizer is allowed* NOTE: *May be administered
concurrently with radiotherapy; may be in addition to a single line of therapy for
locally advanced or metastatic disease

Endocrine therapy

- Not specified

Radiotherapy

- See Chemotherapy

- More than 4 weeks since prior myelotoxic radiotherapy (more than 3,000 cGy to fields
including substantial bone marrow) and recovered

- No concurrent radiotherapy

Surgery

- At least 4 weeks since prior surgery for cancer of the urothelium (except nephrostomy
tubes and ureteral stents)

Other

- At least 4 weeks since any prior therapy and recovered

- No other concurrent investigational or commercial agents or therapies intended to
treat the malignancy

- No concurrent combination antiretroviral therapy for HIV-positive patients
We found this trial at
12
sites
2300 N. Edward Street
Decatur, Illinois 62526
217-876-8121
Decatur Memorial Hospital Cancer Care Institute An American flag bearing only 48 stars waved above...
?
mi
from
Decatur, IL
Click here to add this to my saved trials
11143 Parkview Plaza Dr # 100
Fort Wayne, Indiana 46845
(260) 484-8830
Fort Wayne Medical Oncology and Hematology Fort Wayne Medical Oncology and Hematology provides state-of-the-art cancer...
?
mi
from
Fort Wayne, IN
Click here to add this to my saved trials
?
mi
from
Chicago, IL
Click here to add this to my saved trials
Evanston, Illinois 60201
?
mi
from
Evanston, IL
Click here to add this to my saved trials
?
mi
from
Hamilton,
Click here to add this to my saved trials
One Ingalls Drive
Harvey, Illinois 60426
708.333.2300
Ingalls Cancer Care Center at Ingalls Memorial Hospital As the area's only independent not-for-profit healthcare...
?
mi
from
Harvey, IL
Click here to add this to my saved trials
2160 S. First Ave.
Maywood, Illinois 60153
888-584-7888
Cardinal Bernardin Cancer Center at Loyola University Medical Center The Cardinal Bernardin Cancer Center is...
?
mi
from
Maywood, IL
Click here to add this to my saved trials
8800 W. Doyne Avenue
Milwaukee, Wisconsin 53226
(414) 805-6840
Medical College of Wisconsin Cancer Center Cancer touches everyone in our community, and for many,...
?
mi
from
Milwaukee, WI
Click here to add this to my saved trials
?
mi
from
Peoria, IL
Click here to add this to my saved trials
Saint Joseph, Michigan 49085
?
mi
from
Saint Joseph, MI
Click here to add this to my saved trials
South Bend, Indiana 46601
?
mi
from
South Bend, IN
Click here to add this to my saved trials
Springfield, Illinois 62701
?
mi
from
Springfield, IL
Click here to add this to my saved trials